Novartis’ Jakavi bests current therapy for GvHD
REACH2 is the first Phase III study in steroid-refractory acute graft-versus-host-disease (GvHD) to have met its primary endpoint
Read More
Tag: Jakavi
Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm
Early clinical evidence suggests that the JAK inhibitor could reduce the number of patients requiring intensive care and mechanical ventilation
Read More
SMC green light for rare blood cancer treatment
NHS funding was backed for four medicines
Read More
Novartis’ Jakavi comes out on top in rare blood cancer trial
New data shows Novartis’ Jakavi to be superior than best available therapy in patients with the rare haematological cancer polycythemia vera (PV), which affects around 100,000 people globally a year.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
